Affordable Access

deepdyve-link
Publisher Website

Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease.

Authors
  • Zhang, Rui Long1
  • Lo, Hang Hong1
  • Lei, Cheng2
  • Ip, Nikki1
  • Chen, Juan3
  • Law, Betty Yuen-Kwan4
  • 1 State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macao, SAR China. , (China)
  • 2 Department of Pediatrics, Kiang Wu Hospital, Macao, SAR China. , (China)
  • 3 The Key Laboratory of Molecular Biology of Infectious Diseases Designated by the Chinese Ministry of Education, Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. Electronic address: [email protected] , (China)
  • 4 State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macao, SAR China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
Current opinion in pharmacology
Publication Date
Sep 18, 2020
Volume
54
Pages
72–81
Identifiers
DOI: 10.1016/j.coph.2020.08.008
PMID: 32956895
Source
Medline
Language
English
License
Unknown

Abstract

Kawasaki disease is an acute childhood self-limited vasculitis, causing the swelling or inflammation of medium-sized arteries, eventually leading to cardiovascular problems such as coronary artery aneurysms. Acetylsalicylic acid combined with intravenous immunoglobulin (IVIG) is the standard treatment of Kawasaki disease (KD). However, a rising number of IVIG resistant cases were reported with severe disease complications such as the KD Shock Syndrome or KD-Macrophage activation syndrome. Recent reports have depicted the overlapped number of children with SARS-CoV-2 and KD, which was called multisystem inflammatory syndrome. Simultaneously, the incidence rate of KD-like diseases are increased after the outbreak of COVID-19, suggesting the virus may be associated with KD. New intervention is important to overcome the problem of IVIG treatment resistance. This review aims to introduce the current pharmacological intervention and possible resistance genes for the discovery of new drug for IVIG resistant KD. Copyright © 2020 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times